Policy & Regulation
Pfizer reports positive Phase 3 results for LITFULO in nonsegmental vitiligo
30 July 2026 - US biopharmaceutical company Pfizer Inc (NYSE:PFE) on Thursday announced positive topline results from two Phase 3 trials evaluating LITFULO (ritlecitinib) as a potential oral systemic ...
Octapharma to build USD1.5bn critical care manufacturing facility in Rock Hill, SC
30 July 2026 - Switzerland-based plasma fractionator Octapharma on Wednesday announced plans to establish its first-ever US-based manufacturing and production site at the Palmetto Research Park in Roc...
Ractigen Therapeutics closes over USD31m financing for project advancement
30 July 2026 - Ractigen Therapeutics, a clinical-stage biotechnology company developing small activating RNA (saRNA) therapeutics and advanced extrahepatic delivery systems, announced on Wednesday the...
10x Genomics and Lausanne University Hospital to collaborate on cancer care research
30 July 2026 - Life science technology company 10x Genomics Inc (Nasdaq:TXG) on Wednesday announced a research collaboration with Lausanne University Hospital (CHUV), a Swiss academic medical centre, ...
European Commission approves RINVOQ for severe alopecia areata
29 July 2026 - US biopharmaceutical company AbbVie (NYSE: ABBV) said on Wednesday it has received European Commission approval for RINVOQ (upadacitinib) to treat adults and adolescents aged 12 and ove...
AbCellera and Vertex agree collaboration to develop multispecific T-cell engagers
29 July 2026 - Clinical-stage biotechnology company AbCellera Biologics Inc (Nasdaq:ABCL) announced on Wednesday that it has entered into a collaboration with biopharmaceutical company Vertex Pharmace...